El interés en corto de Ionis Pharmaceuticals da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Ionis Pharmaceuticals. Los datos de interés en corto se actualizan cada dos semanas.

Ionis Pharmaceuticals (NASDAQ:IONS) Bolsa, Informe de interés en corto

Ionis Pharmaceuticals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals Inc

Trading Ideas

BULL

Webull Shares Halted On Circuit Breaker To The Upside, Stock Now Down -19.3%

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is presently auctioning around our critical pivot of 540.07. Bulls should aim for an immediate ascent toward 541.49. Sustained bullish activity above 541.49 may spark a further advance towards our significant support at 544.04. If buyers successfully stabilize above this point during regular hours, watch for continued upside momentum to test the next significant area at 546.46, with an ultimate bullish ambition of reaching 548.13.
If buyers fail to secure the 540.07 mark, bearish forces will likely challenge the integrity of the 539.18 support. Increased sell-side activity here would set up a further decline toward the 537.20 area. Should selling pressure intensify, anticipate a significant test lower at 535.43. If selling accelerates fiercely, our downside target for the bears today is positioned at 534.17.
Invesco QQQ Trust Series 1 (QQQ)
The Q&#8217;s are currently hovering near the pivotal price of 458.83. For bullish momentum to take hold, buyers need to firmly establish support at this level and push the auction upward toward the resistance at 462.14. Continued buying strength could further elevate the market to test the critical resistance at 463.56. With substantial bullish commitment, anticipate an aggressive push toward today&#8217;s bullish target at 467.60, passing through an intermediate hurdle at 465.93.
Conversely, if 458.83 falters as reliable support, sellers will likely seize control and drive prices lower, targeting the level at 456.23. Should bearish sentiment persist at this level, further downward pressure toward 455.29 could ensue. Continued sell-side aggression might lead to a significant support test at 454.10, and ultimately, if selling intensifies, we could see prices challenging our bearish target at 450.98.
Apple Inc. (AAPL)
Apple shares are presently auctioning around the critical pivot of 202.29. Bulls need to anchor securely above this mark and push upwards toward 203.48 to establish a new base of support. A solid bullish drive past this area would invite further bullish attention toward 205.54. Persistent buying could open doors for Apple to aim directly at today&#8217;s upper bullish target, pegged at 206.55.
Should 202.29 weaken under selling pressure during today&#8217;s regular session, expect bears to quickly test the lower boundary at 200.53. Ongoing bearish activity could push Apple down toward 199.51. Continued selling intensity may further challenge 198.79. Failure to hold at this point would likely push the auction down toward our final bearish objective of 198.22.
Microsoft Corp. (MSFT)
Microsoft is auctioning around our crucial area of interest at 389.29. For bulls, maintaining a strong foothold above 390.98 would likely ignite bullish momentum, aiming for a test of 393.47, establishing it firmly as support. A successful consolidation here could set the stage for additional bullish exploration toward 394.46. Sustained buying enthusiasm would likely propel Microsoft toward our ultimate bullish target for today at 397.65.
If sellers gain traction and break below 389.29 during today&#8217;s session, we anticipate an immediate test lower at 388.53. Further selling pressure breaking this level could lead to bearish expansion toward 386.09. Persistent downward momentum would bring into focus the support at 384.57, and on heightened bearish intensity, the price might slide towards today&#8217;s bearish target of 382.69.
NVIDIA Corporation ( NVDA)
NVIDIA is currently auctioning around our critical point of 110.73. Bulls will need immediate strength to challenge and sustain trading above 111.70, converting this resistance into a new base of support. Success here would likely encourage further buying toward 112.54. Continued bullish activity could propel prices higher toward 113.68, with our ultimate bullish goal for today set at 115.83.
Conversely, failure to maintain support at 110.73 during today&#8217;s auction would likely result in bears pressing toward 109.86. If selling intensifies below this zone, expect further bearish moves toward 109.12. A sustained bearish auction could see an extended test of support at 107.51. With ongoing downward pressure, today&#8217;s bearish objective sits significantly lower at 106.30.
Alphabet Inc Class A (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)
Alphabet is currently trading near the pivotal price of 160.36. Bulls need to strongly secure support at 161.79 and then carry momentum upwards toward 163.79. Continued bullish commitment may allow Alphabet shares to ascend toward today&#8217;s upper bullish objective at 165.41, provided market strength persists.
If the 160.36 price mark breaks down, expect sellers to promptly test lower support at 158.54. Sustained selling activity beneath this area would set the stage for further downside exploration toward 156.61. In the event of heavy sell-side pressure, a deep bearish push toward our ultimate bearish target today at 154.95 should not be ruled out.
Meta Platforms Inc ( META)
Meta is currently trading around our crucial benchmark of 534.33. Bullish traders must firmly establish this level as support to drive price upward toward the next significant resistance at 537.68. If buyers assert sustained strength here, anticipate a further rise toward the level of 541.79. Persistent bullish activity today could ultimately push Meta toward our ambitious bullish target of 548.44.
On the flip side, should the 534.33 support fail to hold during regular trading hours, bears will likely seek to aggressively target downside levels, initially probing support at 531.03. Continuation of bearish momentum could further pressure prices toward 529.29. If the bearish trend intensifies, anticipate further deterioration toward today&#8217;s bearish goal at 520.27.
Tesla Inc. ( TSLA)
Tesla is currently auctioning near our pivotal reference price of 250.25. To initiate bullish momentum, buyers must decisively push upward toward 252.38. Continued bullish conviction would likely extend the rally toward the important level of 254.28. If today&#8217;s broader market sees bullish conviction, expect Tesla to test the higher level at 256.34. With substantial bullish buying, the price might reach today&#8217;s primary bullish target at 259.81.
If Tesla struggles to sustain support at 250.25, anticipate bearish efforts to target the lower boundary at 248.37. Increased selling here would likely press the auction further down toward 246.16. If bearish momentum continues to dominate and this support breaks, Tesla could descend toward today&#8217;s primary bearish target of 243.98.
Final Word:&nbsp;
Today&#8217;s trading session kicks off with crucial economic data releases, including the Empire Manufacturing Index for April and the Import and Export Price Index for March at 8:30 AM ET. Market participants should also stay tuned for the Treasury&#8217;s 52-week Bill Auction scheduled at 11:30 AM ET. Additionally, Federal Reserve officials Barkin at 11:35 AM ET, and Cook at 6:10 PM ET will deliver remarks, potentially providing fresh insights into monetary policy direction and economic expectations.&nbsp;
Traders will likely remain highly responsive to developments in the ongoing trade disputes, specifically concerning tariff negotiations and economic diplomacy. This combination of economic releases and geopolitical uncertainties could introduce volatility, making today a session that demands careful risk management. Trade with discipline and stay informed. Good luck in today&#8217;s markets!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it&#8217;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

GOOGL

Technical Analysis For SPY And Top Tech Stocks Amid Bearish Sentiment

PNC Financial Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) reported first-quarter results on Tuesday, where earnings per share of $3.51 outpaced <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44808348/pnc-reports-first-quarter-2025-net-income-of-1-5-billion-3-51-diluted-eps" rel="noreferrer noopener">the analyst consensus estimate of $3.39.</a>
Quarterly sales of $5.452 billion missed the street view of $5.489 billion. Revenues gained 6% year over year in the quarter under review.
Net interest income grew 6% year over year to $3.476 billion, thanks to the benefit of lower funding costs and the continued repricing of fixed rate assets. The net interest margin was 2.78%, increasing by 21 basis points from the first quarter of 2024.
Noninterest income grew&nbsp;5% to&nbsp;$1.976 billion, driven by business growth across all fee categories except residential mortgage revenue.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43109519/pnc-financial-positioned-for-strong-loan-expansion-and-yield-curve-benefits-analyst-predicts-net-interest-income-growth-through-2026" rel="noreferrer noopener">PNC Financial Positioned For Strong Loan Expansion And Yield Curve Benefits, Analyst Predicts Net Interest Income Growth Through 2026</a>
Provision for credit losses was&nbsp;$219 million&nbsp;in the first quarter&nbsp;(vs.&nbsp;$155 million a year ago), reflecting changes in macroeconomic factors and portfolio activity.
CET1 capital ratio stood at&nbsp;10.6% vs. 10.1% in the prior year quarter.&nbsp;
PNC Financial said it distributed $0.8 billion to shareholders, including $0.6 billion in common stock dividends and $0.2 billion through share buybacks.
Dividend: On&nbsp;April 3, 2025, the company declared a quarterly cash dividend on common stock of&nbsp;$1.60&nbsp;per share to be paid on&nbsp;May 5, 2025.
The company said that second-quarter 2025 share repurchase activity is expected to approximate recent quarterly average levels.
Outlook: For FY25, the company <a href="https://d1io3yog0oux5.cloudfront.net/_f0758380726194a0ece577bf70a3c374/pnc/db/2250/21537/presentation/4Q24+Earnings+Slides_Final.pdf" target="_blank" rel="noreferrer noopener">reiterated </a>its outlook. PNC Financial <a href="https://d1io3yog0oux5.cloudfront.net/_f0758380726194a0ece577bf70a3c374/pnc/db/2250/21552/presentation/1Q25+Earnings+Slides_Final.pdf" target="_blank" rel="noreferrer noopener">expects </a>net interest income to increase 6% to 7%, non-interest income to increase 5%, <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noopener">and total revenue to increase</a><a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener"> 6%.</a>
For the second quarter, the firm expects net interest income to be up 1%-2% compared to the first quarter of 2025, and total revenue to increase by 1% to 3%.
Price Action: PNC shares were trading higher by 0.45% to $156.02 premarket at last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44807995/us-stock-futures-waver-after-two-day-rally-trumps-tariff-moves-could-end-a-3-year-rolling-recession-says-expert" target="_blank" rel="noreferrer noopener">US Stock Futures Waver After Two-Day Rally: Trump&#8217;s Tariff Moves Could End A 3-Year &#8216;Rolling Recession,&#8217; Says Expert</a></li>
</ul>
Photo: Shutterstock

Earnings

News

Guidance

Markets

Movers

General

PNC Financial Tops Q1 Earnings Estimates Despite Revenue Miss, Credit Loss Provisions Rise

Citigroup analyst Ronald Josey maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Buy and lowers the price target from $98 to $87.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Zillow Gr, Lowers Price Target to $87

SKYE

Skye Bioscience Shares Halted On Circuit Breaker To The Upside, Stock Now Up 119.8%

Citigroup analyst Thomas Palmer maintains Darling Ingredients (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) with a Buy and lowers the price target from $45 to $44.

Citigroup Maintains Buy on Darling Ingredients, Lowers Price Target to $44

<ul>
<li>A CryptoQuant analyst has suggested it might be time for investors to load up on altcoins.</li>
<li>The analyst&#8217;s view is based on a key chart.</li>
<li>Other analysts have also expressed similar views, but the tide may not lift all boats.</li>
</ul>
Over the past few months, the volatility of altcoins, which makes them appealing to investors with high-risk tolerance, has again proven to be a double-edged sword. Amid <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44720918/trump-tariffs-are-pressuring-bitcoin-bonds-commodities-vaneck-warns">broader market uncertainty</a>, most altcoins have tanked over 50% from their Q4 2024 highs.
But now, one analyst suggests that a reversal may be on the horizon.
<h2 class="wp-block-heading">Altcoins In &#8220;A Buying Zone?&#8221;</h2>
&#8220;It might be time to start a DCA strategy on altcoins,&#8221; CryptoQuant analyst &#8220;Darkfost&#8221; asserted in a <a href="https://cryptoquant.com/insights/quicktake/67f803c60c912a79521675da-It-might-be-time-to-start-a-DCA-strategy-on-altcoins?utm_source=twitter&amp;utm_medium=sns&amp;utm_campaign=quicktake&amp;utm_content=darkfost">report</a> on Thursday.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
DCA, short for dollar-cost averaging, is a popular investment strategy where a fixed amount of money is invested at regular intervals regardless of price action. By suggesting that investors start a DCA altcoin strategy, Darkfost is encouraging investors to load up on altcoins in anticipation of a potential rally.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It might be time to start a DCA strategy on Altcoins. "We've entered a buying zone, which is defined by the 30-day moving average falling below the annual average&#8230; last time we reached these levels was in September 2023, right after the bear market ended." – By <a href="https://twitter.com/Darkfost_Coc?ref_src=twsrc%5Etfw">@Darkfost_Coc</a> <a href="https://t.co/xEHnHD5bg8">pic.twitter.com/xEHnHD5bg8</a>
&mdash; CryptoQuant.com (@cryptoquant_com) <a href="https://twitter.com/cryptoquant_com/status/1910591153683997022?ref_src=twsrc%5Etfw">April 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The analyst&#8217;s view is based on an intersection of moving averages on the Aggregated Altcoin Trading Volume for Stablecoin Quote Pairs chart, tracking volumes across multiple altcoin pairs.&nbsp;
Darkfost argues that altcoins have recently entered &#8220;a buying zone,&#8221; as the 30-day moving average on this chart has fallen below the annual average.
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
The analyst highlighted that this last occurred in September 2023, before the beginning of the bullish market run that continued in 2024.
&#8220;These phases can last several weeks or even months, but historically, they&#8217;ve consistently offered attractive opportunities to set up a DCA strategy,&#8221; the CryptoQuant analyst stressed.
Darkfost is not the only analyst recently suggesting that an altcoin rally may be on the horizon.&nbsp;
<h2 class="wp-block-heading">A Selective Rally?</h2>
In an April 3 <a href="https://x.com/RaoulGMI/status/1907885565640319262?t=SRh2Bb912kY-JhIUaqYV1g&amp;s=19">livestream</a>, Real Vision Chief Crypto Analyst Jamie Coutts argued that altcoins still had gas for one more impulsive move in the current market cycle, eying June for the start of such a rally. But Coutts cautioned that the tide would not lift all boats, instead urging investors to look out for assets seeing a bump in network activity.
This view suggests that the coming rally may not be the all-out &#8220;altcoin season&#8221; that market participants have been pining for since the recent bull run kicked off. It aligns with <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43877698/alt-season-has-begun-expert-says-but-will-ethereum-xrp-solana-benefit">recent arguments from CryptoQuant CEO Ki Young Ju</a> that the dynamics of crypto altcoin season have changed.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Altcoin season is a bull market phase during which altcoins record substantial price increases, significantly outperforming Bitcoin. It has historically been the result of capital rotation from Bitcoin as investors seek higher beta plays. As such, the historical sign for altcoin season has been a decline in Bitcoin dominance.
But with the emergence of proxies like MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and spot exchange-traded funds, Young Ju contended that the cord between Bitcoin and altcoins has been broken. Further, he argued that the metric to watch was no longer Bitcoin dominance but trading volumes, theorizing that coins that will make it will be the ones with paper wrappers like ETFs or ecosystems based on stablecoins or Bitcoin.
Nonetheless, any potential altcoin rally will likely depend on an improvement in the current macroeconomic conditions, as uncertainty sparked by <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44754189/bitcoin-ethereum-dogecoin-tumble-as-trump-ups-china-tariffs-scraps-irs-rule-in-nod-to-crypto-voters-rising-yuan-could-boost-altcoins-says-analyst">President Donald Trump&#8217;s tariff policy</a> discourages investments in risk assets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Personal Finance

MSTR

Why This Analyst Says 'It Might Be Time To Start A DCA Strategy On Altcoins'

Citigroup analyst Thomas Palmer maintains Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) with a Neutral and raises the price target from $76 to $77.

Citigroup Maintains Neutral on Bunge Global, Raises Price Target to $77

WIIM

Hewlett Packard Enterprise shares are trading higher after Bloomberg reported Elliott Investment Management has built a stake over $1.5 billion in the company.

<a href="https://www.bloomberg.com/news/articles/2025-04-15/elliott-is-said-to-take-over-1-5-billion-stake-in-hp-enterprise" title="https://www.bloomberg.com/news/articles/2025-04-15/elliott-is-said-to-take-over-1-5-billion-stake-in-hp-enterprise">https://www.bloomberg.com/news/articles/2025-04-15/elliott-is-said-to-take-over-1-5-billion-stake-in-hp-enterprise</a>

Bloomberg: 'Elliott to Take Over $1.5 Billion Stake in HP Enterprise'

HSBC analyst Vikram Gandhi upgrades KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) from Hold to Buy and lowers the price target from $170 to $119.

Upgrades

HSBC Upgrades KKR to Buy, Lowers Price Target to $119

Skye Bioscience Shares Halted On Circuit Breaker To The Upside, Stock Now Up 52.7%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham analyst Chris Pierce initiated coverage on Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) with a Buy rating and announced a price target of $10. Aurora Innovation shares closed at $6.03 on Monday. <a href="https://www.benzinga.com/quote/AUR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Andrew Andersen initiated coverage on SiriusPoint Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPNT#NYSE">SPNT</a>) with a Hold rating and announced a price target of $17. SiriusPoint shares closed at $16.43 on Monday. <a href="https://www.benzinga.com/quote/SPNT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Adam Maeder initiated coverage on RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) with a Neutral rating and announced a price target of $18. RxSight shares closed at $14.42 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AUR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="580" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15083302/image-114-1024x580.png" alt="" class="wp-image-872123" style="width:571px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15083302/image-114-1024x580.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15083302/image-114-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15083302/image-114-768x435.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15083302/image-114.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44806916/citigroup-bank-of-america-and-3-stocks-to-watch-heading-into-tuesday">Citigroup, Bank Of America And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

HUBS

RXST

SPNT

This Aurora Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday

Citigroup analyst Thomas Palmer maintains Archer-Daniels-Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) with a Neutral and lowers the price target from $51 to $49.

Citigroup Maintains Neutral on Archer-Daniels-Midland, Lowers Price Target to $49

The statistically significant responder analysis results for Mytesi&#xAE; (crofelemer) in the Phase 3 <a href="https://clinicaltrials.gov/study/NCT04538625">OnTarget</a> study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the <a href="https://sabcs.org/Symposium-Overview-2024">San Antonio Breast Cancer Symposium</a>
Late-breaker abstract accepted by <a href="https://mascc.org/annualmeeting2025/">MASCC</a> shows additional significant results for breast cancer subgroup
Jaguar planning to meet with FDA in Q2 2025 to discuss possible pathways for crofelemer approval for prophylaxis of diarrhea in patients with breast cancer
A second late-breaker abstract, related to the results of a screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 15, 2025 / <a href="https://pr.report/9ein">Jaguar Health, Inc.</a> <a href="https://pr.report/9eio">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or the "Company") family company Napo Pharmaceuticals ("Napo") today announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget study has been accepted for presentation as an oral rapid e-poster at MASCC's June 26-28, <a href="https://pr.report/9eip">2025 Annual Meeting</a> in Seattle, Washington. The authors include Pravin Chaturvedi, PhD, who is Jaguar's Chief Scientific Officer and Chair of Napo's Scientific Advisory Board, as well as leading oncologists and cancer patient advocates.
The abstract is titled OnTarget: Crofelemer or Placebo for the Prophylaxis of Diarrhea in Adults with Solid Tumors Initiating Targeted Therapy ± Chemotherapy (Tt/C)
"We're very pleased about the acceptance by MASCC of this new abstract, which describes the proportion of breast cancer patients who were continuous responders for the entire 3-month period of the OnTarget trial compared to breast cancer patients in the placebo arm of the study," said Lisa Conte, Jaguar's president and CEO.
"As a cancer patient, having options to manage the side effects of life saving drugs is very important. I believe the published results of crofelemer for the prophylaxis of cancer therapy-related are very exciting and compelling," said Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who serves on Napo's Scientific Advisory Board (SAB).
As announced, the U.S. Food and Drug Administration (FDA) has granted Napo a Type C Meeting in the second quarter of 2025 to discuss the responder analysis in the prespecified subgroup of patients with breast cancer for crofelemer in Napo's Phase 3 OnTarget trial. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy. The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025,1 and it's estimated that there were 4 million US women with a history of invasive breast cancer in 2022.2
"Diarrhea is a common side effect of targeted cancer therapies and can lead to dose changes, treatment delays, or cessation of treatment altogether, all of which can impact patient outcomes. We are very happy to have been granted a meeting with the FDA to review the positive OnTarget results in breast cancer patients and our goal is to discuss the most efficient pathways to make crofelemer - our novel, oral plant-based prescription medicine - available to this patient population for cancer therapy-related diarrhea (CTD)," said Conte.
Members of Napo's SAB are expected to join Jaguar representatives at the FDA meeting in the second quarter of 2025.
As previously announced, the initial top line results from the OnTarget study showed that the multicenter, double-blind, placebo-controlled pivotal clinical trial did not meet its primary endpoint for the prespecified analysis of all tumor types. The subgroup analysis in adult breast cancer patients indicates that crofelemer achieved significant results in this subgroup.
Napo today also announced that a second late-breaker abstract, related to the results of a recent Napo-sponsored screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting. The abstract is titled Beyond the Pain: Patient Insights on Oral Mucositis in Cancer Treatment.
"Oral mucositis is a common, painful, and life-altering side effect of cancer treatment, frequently disrupting eating, speaking, sleeping, and social interactions. Capturing real-world patient experiences and insights can help to identify patient priorities and co-create solutions to support prevention and management of oral mucositis and enhance quality of life," said Stacey Tinianov, 11-year cancer survivor and founder of <a href="https://pr.report/9eiq">Advocates for Collaborative Education</a> who serves on Napo's SAB. "I am delighted and honored that the results of the screening survey and focus group will be presented at MASCC's Annual Meeting this June."
Ms. Tinianov coordinated the screening survey and focus group in conjunction with cancer patients who serve as Ambassadors for Napo's ongoing <a href="https://pr.report/9eir">Make Cancer Less Shitty</a> (MCLS) patient advocacy program. The goal of the MCLS program is to drive awareness of cancer supportive care gaps and needs, bring together patients, advocates, researchers, and clinicians, and, most importantly, to amplify the voice of patients about the importance of supportive care.
"Oral mucositis has impacted my daily life constantly since 2016. Without proper supportive care, I have raw mouth sores and ulcerations from my gums and lips all the way down my throat. When severe, it impacts what I am able to eat, how I'm able to eat, and sometimes my ability to talk. The pain and irritation from oral mucositis affects my sleep and my self-confidence," said JJ Singleton, a metastatic colon cancer survivor and an Ambassador for Napo's MCLS patient advocacy program.
<a href="https://pr.report/9eis">MASCC</a> is an international, interdisciplinary organization dedicated to the practice, education and research of supportive care in cancer. The organization's mission is to continually improve the supportive care of people with cancer - from diagnosis through to survival or end-of-life care.

JAGX

Jaguar Health Says Late-Breaker Abstract On Addl Results In Adult Breast Cancer Patients From OnTarget Study Accepted For Presentation As Oral Rapid E-poster At MASCC Annual Meeting

Keybanc analyst Eric Gonzalez maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Overweight and lowers the price target from $64 to $60.

Keybanc Maintains Overweight on Chipotle Mexican Grill, Lowers Price Target to $60

Citigroup analyst Patrick Cunningham maintains Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) with a Neutral and lowers the price target from $85 to $64.

Citigroup Maintains Neutral on Albemarle, Lowers Price Target to $64

TMO closes near the high of the day
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/14212258/Screenshot-2025-04-14-at-5.14.58%E2%80%AFPM-1024x808.png" alt="" class="wp-image-10614" /></figure>
Thermo Fisher Scientific Inc. (TMO) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:01 AM on April 14th, a significant trading signal occurred for Thermo Fisher Scientific, Inc. (TMO) as it demonstrated a Power Inflow at a price of $444.92. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in TMO&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in TMO&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for TMO, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:The price at the time of the Power Inflow was $444.92. The returns on the High price ($450.84) and Close price ($449.33) after the Power Inflow are respectively 1.3% and 1.0%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past Results Not indicative of Future Results

Thermo Fisher Scientific Stock Up 1.3% After Key Signal

Keybanc analyst Justin Patterson maintains DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Overweight and lowers the price target from $240 to $230.

DASH

Keybanc Maintains Overweight on DoorDash, Lowers Price Target to $230

Barclays analyst Ramsey El-Assal maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Overweight and lowers the price target from $110 to $80.

PYPL

Barclays Maintains Overweight on PayPal Holdings, Lowers Price Target to $80

Press Releases

Ionis to hold fourth quarter and full year 2024 financial results webcast

Ionis reports fourth quarter and full year 2024 financial results

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

Ionis to present at upcoming investor conferences

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

Health Care

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

Comments

Ionis Pharmaceuticals

Interés en corto

Ionis Pharmaceuticals (NASDAQ:IONS) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL